about
The molecular basis of folate salvage in Plasmodium falciparum: characterization of two folate transportersFunctional characterization and target validation of alternative complex I of Plasmodium falciparum mitochondriaOpen-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (Lapdap) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malariaOptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimensPharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment durationUltrasound enhanced detection of individual meningococcal serogroups by latex immunoassay.The plasma membrane of microaerophilic protists: oxidative and nitrosative stress.The digestive food vacuole of the malaria parasite is a dynamic intracellular Ca2+ store.Chapter 17 Type II NADH: quinone oxidoreductases of Plasmodium falciparum and Mycobacterium tuberculosis kinetic and high-throughput assays.Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assayContinued cytoadherence of Plasmodium falciparum infected red blood cells after antimalarial treatment.A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.An acid-loading chloride transport pathway in the intraerythrocytic malaria parasite, Plasmodium falciparumPfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX.Identification of novel antimalarial chemotypes via chemoinformatic compound selection methods for a high-throughput screening program against the novel malarial target, PfNDH2: increasing hit rate via virtual screening methods.Loss of pH control in Plasmodium falciparum parasites subjected to oxidative stress.Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1Potent antihematozoan activity of novel bisthiazolium drug T16: evidence for inhibition of phosphatidylcholine metabolism in erythrocytes infected with Babesia and Plasmodium spp.Antimalarial pharmacology and therapeutics of atovaquoneIdentification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expressionIdentification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malariaHDQ, a potent inhibitor of Plasmodium falciparum proliferation, binds to the quinone reduction site of the cytochrome bc1 complex.Malaria parasite transporters as a drug-delivery strategy.Current drug development portfolio for antimalarial therapies.Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis.A medicinal chemistry perspective on 4-aminoquinoline antimalarial drugs.Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7.Antitubercular pharmacodynamics of phenothiazinesGlycerol: an unexpected major metabolite of energy metabolism by the human malaria parasite.Novel inhibitors of the Plasmodium falciparum electron transport chain.The proliferating cell hypothesis: a metabolic framework for Plasmodium growth and development.Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potentialA validated bioluminescence-based assay for the rapid determination of the initial rate of kill for discovery antimalarials.Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex.Characterization of the choline carrier of Plasmodium falciparum: a route for the selective delivery of novel antimalarial drugs.The malaria parasite type II NADH:quinone oxidoreductase: an alternative enzyme for an alternative lifestyle.A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.Structural optimization of quinolon-4(1H)-imines as dual-stage antimalarials: toward increased potency and metabolic stability.
P50
Q27972580-C03D5F3D-E108-4398-9AC5-664969E2C681Q27973427-0E1688F5-324B-4970-9CE1-7F04A9908921Q28472247-8564036F-0F50-44F8-9D8F-5ACFC1FD6DD2Q28831110-B74757DD-955D-4FAF-8B98-AF90FE53B0C4Q30377051-5E869287-5FF0-464A-9D39-39189337ED3AQ30502909-12BDBEFE-2849-47DE-9081-F8B2B7752E0BQ30831173-70CCBA28-2C5E-4DE7-A66A-8CF96F2A23CAQ31141787-F95BEDF8-A9D6-4FF3-9E8C-82E8CFCE3B4EQ33427271-D9E23F6C-2E55-441F-8C09-842C4F506530Q33604021-A98F565F-5564-4FD5-A6D5-23E41866FCDFQ33621397-32C6D82A-8B1B-4E8F-AB73-0AB74B19533CQ33761137-AC733CEA-1247-4F08-841E-4D35609DBDA1Q33897865-EF234184-0AC5-46F2-A843-EA185744857DQ34145273-473CA866-8C09-4D81-B54D-739DF4CA9DADQ34180451-92CFE88A-0852-4A14-9C7D-6D452EFC1533Q34639441-9272AAD4-B720-4E6D-AD1B-2E2BBB09D0C7Q35031417-78D61E4D-D934-49FB-8B5E-40A22DF303DCQ35091518-37E02DA1-56BE-4971-A6C9-B9F558DE4638Q35131253-A3A7A514-5188-40ED-892B-8D73721C3FDBQ35814421-8922D12B-E64D-4D6B-97C1-A3A84C488D25Q35879955-7F773010-4632-40E1-B155-8A44CCE92E53Q35958086-DD0959EA-D93F-4B86-91D4-C587F1DC844DQ35991425-BB4CEFD3-D531-4B70-879F-51CEFDFA5858Q36086330-6EF8129C-18A1-4BAB-BB82-6D6914F105BAQ36143567-C7D2F59A-895B-4657-9EF4-F631E7CD2D94Q36220900-691B1DE7-8BF6-4528-9EF7-A42684580D5EQ36311780-9395DAAF-A317-42DB-B6FC-5C6F22093A59Q36486219-D9BAFDB0-E350-48EC-B695-B32227D155EFQ36646501-5FAF8115-1C2B-4D89-9BC2-C64EF642421FQ36675149-862D5BCD-5311-4B3E-9704-1B0FC0F8C602Q37139263-17ADC957-0FE6-4CB0-8A9E-A3EAFDCF47E8Q38176703-256933FB-7AE7-41D0-89DB-197E3F00618EQ38196531-874A159A-6218-4433-BE19-4A23A9B2CFADQ38294829-5D61DD71-ED2C-4CBF-AD08-D755128985D2Q38780035-0AAD9021-0326-4C61-9E5C-92B1072B99E5Q38908333-92578FBE-167D-452A-BDE4-CBB4D4189F44Q38908342-CFBD3DBB-BD5A-4743-8164-562593C68202Q39005404-282C5B55-88B2-4350-9FEF-9517EFA51E6AQ39096334-4F2C4213-59F2-431C-9044-55AEFCA86857Q39097903-2FFE05F6-E899-4A89-93B1-93A6E53F4370
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giancarlo Biagini
@ast
Giancarlo Biagini
@en
Giancarlo Biagini
@es
Giancarlo Biagini
@nl
Giancarlo Biagini
@sl
type
label
Giancarlo Biagini
@ast
Giancarlo Biagini
@en
Giancarlo Biagini
@es
Giancarlo Biagini
@nl
Giancarlo Biagini
@sl
prefLabel
Giancarlo Biagini
@ast
Giancarlo Biagini
@en
Giancarlo Biagini
@es
Giancarlo Biagini
@nl
Giancarlo Biagini
@sl
P108
P1053
F-3449-2011
P106
P21
P31
P3829
P496
0000-0001-6356-6595